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A B S T R A C T
In the last decade, it has become clear that anti-cancer therapy is more successful when it can also induce an
immunogenic form of cancer cell death (ICD). ICD is an umbrella term covering several cell death modalities,
including apoptosis and necroptosis. In general, ICD is characterized by the emission of damage-associated
molecular patterns (DAMPs) and/or cytokines/chemokines, leading to the induction of strong anti-tumor im-
mune responses. In experimental cancer therapy, new observations indicate that the immunogenicity of dying
cancer cells can be improved by the use of biomaterials. In this review, after a brief overview of the basic
principles of the concept of ICD and discussion of the potential use of DAMPs as biomarkers of therapy eﬃcacy,
we discuss an emerging role of nanomaterials as a promising strategy to modulate the immunogenicity of cancer
cell death. We address how nanocarriers can be used to increase the immunogenicity of ICD and then turn our
attention to their dual action. Nanocarriers can be used to increase the immunogenicity of dying cancer cells and
to reduce the side eﬀects of chemotherapy. Future studies will show whether biomaterials are truly an optimal
strategy to modulate the immunogenicity of dying cancer cells and will provide the insights needed for the
development of novel treatment strategies for cancer.
1. Introduction
For many years, cancer has remained one of the most serious so-
cially signiﬁcant concerns for world health due to its association with
high mortality and disability. Contemporary anti-tumor treatments
consist mainly of surgery (1st strategy), radiotherapy and che-
motherapy (2nd strategy) and immunotherapy (3rd strategy). In the
treatment of cancer, these strategies are often used in diﬀerent em-
pirical combinations, and radio- and chemotherapy often precede sur-
gery. Not all patients respond to treatment despite its durable eﬀect;
therefore, sometimes it can lead to adverse results. Recent studies in-
dicate that a combination of anti-cancer therapies is most eﬀective
when the therapies work in synergy [1,2]. In recent years, it has been
reported that the 2nd strategy of therapy (chemotherapy and/or
radiotherapy) is more successful when these therapies can also induce
an immunogenic form of cell death (ICD), which is associated with
induction of an anti-tumor immune response that leads to tumor
eradication [3].
One of the main characteristics of cancer cells undergoing ICD is
their ability to emit immuno-stimulatory molecules (Fig. 1), among
which are damage-associated molecular patterns (DAMPs) [4,5] and
cytokines/chemokines, both of which contribute to attraction of an-
tigen presenting cells (e.g. dendritic cells, DCs), which engulf dying
cancer cells [6–8]. This process culminates in the cross-presentation of
antigenic peptides on major histocompatibility complex class I (MHC I)
molecules to CD8+ T cells of the adaptive immune system, one of the
main driving forces of anti-tumor immune responses (Fig. 1). Thus,
triggering ICD-inducing modalities could be a suitable strategy for
killing cancer cells while simultaneously eliciting broad antitumor T
cell responses. However, it has become clear that not all cancer cell
types can die in an immunogenic way, and there is a need to develop
novel strategies that enhance the immunogenicity of cancer cell death.
In this review, after a brief overview of the basic principles of the
ICD concept, we discuss an emerging role for nanomaterials as a
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promising strategy to modulate the immunogenicity of cell death and
how they can be used to increase the immunogenicity of cancer cell
death. We also provide a comprehensive and critical perspective on the
most recent advances in the use of the DAMPs that are associated with
ICD (CRT and HMGB1) as biomarkers of therapy eﬃcacy. Finally, we
raise some questions for future research and discuss how future ﬁndings
could be applied to design novel experimental anti-cancer treatments.
2. ICD concept: in brief
Activation of the immune system in cancer treatment goes back to
the 19th century, when the American surgeon William B. Coley used
infection with a mixture of killed Streptococcus pyogenes and Serratia
marcescens (nowadays called Coley's toxins) to treat patients with non-
operable sarcomas (Box 1). However, because of the rapid development
of chemotherapy and radiotherapy, in subsequent years the role of the
Fig. 1. Immunogenic cancer cell death modalities at a glance.
Immunogenic cell death is an umbrella term covering several cell death modalities, such as apoptosis, necroptosis and caspase-independent cell death. Although these
cell death modalities diﬀer from each other morphologically and biochemically (signaling), they are all characterized by the emission of immune-stimulatory
molecules (i.e., DAMPs and/or chemokines or cytokines). Immunogenic apoptosis is characterized by ROS-based ER stress and induction of autophagy, and its
immunogenicity is caspase-dependent. At the cell surface of immunogenic apoptotic cancer cells, there is exposure of CRT, secretion of ATP, and passive release of
HMGB1 due to plasma membrane rupture. Necroptosis can be induced, for example, by Tet-on inducible expression of RIPK3 or other stimuli (e.g., Poly (I:C))
[29,30]. It is characterized by passive release of ATP and HMGB1, and release of chemokines and cytokines in addition to DAMPs [28,83], which might contribute to
the immunogenicity.
*Although activation of NF-kB has been described as one of the important prerequisites of necroptosis immunogenicity [28], the immunogenicity of NF-kB in-
dependent necroptosis has also been described [29,84]. Recently, it has been reported that BH3 mimetics (ABT-263/ABT-737) can induce a speciﬁc form of cell death
independently from caspase activation, i.e. caspase-independent cell death (CICD) [32]. These BH3 mimetics can cause caspase-independent cell death (CICD), which
is more immunogenic than apoptosis and has greater anti-tumor activity. In the presence of CICD, anti-tumor activity is dependent on NF-kB and the emission of
cytokines/chemokines (e.g. TNF) from dying cancer cells as well as on the preserved immunity of the host. Cancer cells undergoing CICD induce diﬀerentiation of
macrophages into the M1 phenotype. It is noteworthy that necroptosis is not important for the anti-tumor eﬀects of CICD.
#Cancer cells undergoing ICD induce anti-tumor immunity, which has been validated in tumor prophylactic vaccination mice models and in syngeneic tumor models
more closely resembling the therapeutic settings. Induction of ICD promotes DC maturation, which leads to optimal antigen presentation to CD8+ T cells and
induction of anti-tumor immunity, resulting in eﬀective suppression of tumor growth and/or regression of neoplasia.
Abbreviations: ATP, adenosine triphosphate; CICD, caspase-independent cell death; CRT, calreticulin; DC, dendritic cell; ER-stress, endoplasmic reticulum stress;
HMGB1, high-mobility group Box 1; ICD, immunogenic cell death; IFN, interferon; IL, interleukin; MOMP, mitochondrial outer membrane permeabilization; NF-kB,
nuclear factor kappa-light-chain-enhancer of activated B cells; PDT, photodynamic therapy; ROS, reactive oxygen species; TNF, tumor necrosis factor.
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immune system as one of the main players in anti-cancer therapy was
mainly neglected.
After the ﬁrst morphological description of apoptotic cell death [9],
it was ﬁrmly believed that cancer cells undergoing apoptosis steer the
extracellular environment to an anti-inﬂammatory state and thereby
contribute to an immunosuppressive network at the primary tumor site,
promoting further tumorigenesis [10–15]. However, the revival of in-
terest in cancer cell death as a potential activator of the immune
system, which is one of the key elements of successful anti-cancer
therapy, started mainly from the concepts of the “danger theory” by
Polly Matzinger in 1994. This theory states that the immune system can
discriminate self from non-self and distinguish dangerous from in-
nocuous signals [4,5]. The current concept of ICD stands on the
shoulders of the “danger theory.” Although this theory was purely
theoretical at that time, it proposed that antigen presenting cells (APC)
can be activated by danger/alarm signals derived from injured cells,
such as those exposed to pathogens, toxins, or mechanical damage.
Since then, many danger signals and damage associated molecular
patterns (DAMPs) have been proposed. They can be constitutive or
inducible, passively or actively secreted, and derived from the cytosol,
nucleus, mitochondria, or endoplasmic reticulum, or even be part of the
extracellular matrix. They are either proteins that are often modiﬁed by
proteolysis and/or oxidation, or non-proteins, e.g. nucleotides. One
important prerequisite for an immuno-stimulatory molecule to be
considered a DAMP is that it has a mainly non-immunological function
inside cells but acquires immuno-stimulatory properties once it is ex-
posed outside the cells.
In the late nineties, several reports appeared on the immuno-sti-
mulatory role of cells undergoing apoptosis (Box 2) and their ability to
induce the maturation of APC [16]. The ICD concept states that certain
types of anti-cancer treatments, such as chemotherapeutics (e.g.
anthracyclines and oxaliplatin) [3], gamma-irradiation [17,18] and
photodynamic therapy [19] induce a speciﬁc form of apoptosis, namely
immunogenic apoptosis (Box 2). This form of cell death is associated
with the emission of DAMPs (e.g. surface exposure of CRT, secretion of
ATP and release of HMGB-1). DAMPs function as adjuvants that sti-
mulate the innate and adaptive immune systems by activating mem-
brane-bound or cytoplasmic pattern recognition receptors (PRRs, e.g.
Toll-like receptor, TLR-4), phagocytic or scavenger receptors (e.g. LDL-
receptor-related protein, LRP1/CD91), and purinergic receptors (e.g.,
P2RX7/P2RY2). Induction of the maturation of DCs by DAMPs med-
iates the induction of the anticancer immune response. Apoptosis is the
ﬁrst potentially immunostimulatory cell death modality to be described
[3], in marked contrast to the initial notion that it is a silent or anti-
inﬂammatory mode of cell death [10–15].
The immunogenicity of apoptosis at the molecular level is highly
dependent on the induction of endoplasmic reticulum stress [19–21],
autophagy [22–24] and production of reactive oxygen species [24]. It
has become clear that immunogenicity is linked not only to apoptosis
but also to other cancer cell death modalities, including necroptosis
(Box 2), a regulated from of necrosis [25–27]. Indeed, the recently
described immunogenicity of necroptosis in experimental cancer
models has attracted substantial interest as an alternative strategy for
killing cancerous cells to induce anti-tumor immunity [28–31]. In this
context, triggering other cell death modalities in cancer cells (i.e. ne-
croptosis, a caspase independent cell death [32]) represents an attrac-
tive alternative for overcoming apoptosis resistance, which often occurs
during cancer therapy and is one of the hallmarks of cancer [33]. These
data also suggest that these immunogenic properties are independent of
the type of cell death cancer cells undergo but are dependent on the
type of cancer cells and on cell death stimuli. Therefore, ICD is an
umbrella term covering all cell death types that have immunogenic
Box 1
Cell Death Modalities.
Apoptosis. Morphologically, apoptosis is characterized by chromatin condensation, cleavage of chromosomal DNA into internucleosomal
fragments, cell shrinkage, membrane blebbing and formation of apoptotic bodies without plasma membrane breakdown. Biochemically, it
involves the activation of caspases, a highly conserved family of cysteine-dependent aspartate-speciﬁc proteases that can be inhibited by
zVAD-fmk. Immunologically, apoptotic cell death during physiological processes is anti-inﬂammatory. Importantly, certain types of anti-
cancer therapy can induce a speciﬁc form of apoptosis – immunogenic apoptosis – which can induce maturation of DCs.
Immunogenic apoptosis. This form of cell death has the same morphological characteristics as apoptosis. At the biochemical level, in
addition to caspase activation, the immunogenicity of apoptosis often requires the induction of ER stress and reactive oxygen species (ROS).
It is associated with the emission of DAMPs, such as surface exposure of CRT, secretion of ATP, and release of HMGB1. The immunogenicity
of a cell line is deﬁned based on whether vaccination of immunocompetent mice with in vitro killed cells confers a survival advantage after
subsequent challenge with live cells of the same cell type.
Accidental necrosis. This is an unregulated cell death modality that can be caused by extreme physicochemical stress (e.g., heat shock
and freeze-thawing). It is associated with the release of DAMPs. This cell death type was initially contrasted to apoptosis.
Regulated necrosis. This is an umbrella term covering several necrotic cell death modalities (e.g. necroptosis, ferroptrosis and pyr-
optosis) sharing common morphological features, such as cell and organelle swelling and rupture of the plasma membrane. But these
necrotic cell death modalities are biochemically regulated by diﬀerent mechanisms.
Necroptosis. This cell death mode can be blocked by inhibitors of RIPK1 (e.g. Nec-1 s), RIPK3 (e.g. GSK’872) and MLKL (e.g. necro-
sulfonamide for human cells only). It is characterized by the absence of caspase activation and thus insensitivity to pan-caspase blockers
such as zVAD-fmk. It often occurs when caspase-8 is downregulated or inhibited [25,71]. Necroptosis is associated with emission of DAMPs
(e.g. HMGB1 and ATP) and cytokines/chemokines and is usually immunogenic.
Ferroptosis. This is characterized by iron-dependent ROS production and lipid peroxidation and is executed via oxygenation of poly-
unsaturated phosphatidylethanolamines (PE) by 15-lipoxygenases (15-LO), which normally use free polyunsaturated fatty acids as sub-
strates. It can be induced by reduction of GSH level by blocking the xc− system, the glutamate/cysteine antiporter, or GPX4 activity. PEBP1
is an emerging master regulator of ferroptosis. It can be blocked by blockers of lipid peroxidation (e.g. Fer-1, vitamin E and liproxstatins).
Pyroptosis. This cell death type is initiated by inﬂammasomes, which drive activation of caspase-1 or caspase-11,−4 and− 5, leading
to the cleavage of gasdermin D. It is associated with the release of IL-1β and IL-18.
Entosis. It is a form of epithelial cell cannibalism involving the engulfment of viable cells by non-phagocytic cells of the same
(homotypic) or a diﬀerent (heterotypic) type and leading to formation of a so-called ‘cell-in-cell’ structure. Often (but not always), en-
gulfment is followed by the death of internalized cells. Entosis can be triggered by matrix deadhesion, mitosis and glucose starvation
[72,73].
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properties.
3. DAMPs as biomarkers to assess the eﬃcacy of anti-cancer
therapy
In parallel with the development of the ICD concept, it has become
clear in several cohorts of cancer patients that several DAMPs and
DAMP-associated factors (e.g., DAMP and PRR expression levels, ge-
netic polymorphisms in genes encoding DAMPs or PRR) could have a
prognostic or predictive value. In this section, we focus mainly on CRT
and HMGB1 (Table 1). For discussions of the role of PRR expression
levels in cancer, we direct the reader to recently published reviews
[34,35].
3.1. CRT
Several research groups considered the changes in CRT expression
as a useful indicator in cancer diagnosis and treatment planning
(Table 1). A study on 68 patients with neuroblastoma showed that in-
creased CRT is positively associated with tumor diﬀerentiation and a
favorable outcome. In that study [36], it was shown that increased CRT
expression predicts longer survival of patients with advanced-stage
neuroblastoma. Moreover, the increased CRT levels in urinary samples
could serve as a diagnostic marker of bladder carcinoma [37]. Detec-
tion of the level of CRT expression can also be considered as a powerful
prognostic tool for overall survival of patients. It has been shown in two
independent cohorts of patients with non-small cell lung cancer (re-
ceiving neoadjuvant chemotherapy or not) totaling> 350 patients that
regardless of the type of treatment, high levels of CRT were associated
with longer survival. One of the reasons for the positive dynamics was
activation of adaptive immune responses in the tumor microenviron-
ment and inﬁltration of mature DCs and eﬀector T-cell subsets, which
was possibly triggered by CRT overexpression [38]. That study in-
dicates that CRT can be used as a prognostic biomarker that reﬂects the
state of local anti-tumor immune responses in the lungs. Similar clinical
observations were made on patients with acute myeloid leukemia
(AML). Determination of CRT in the peripheral blood of 50 AML pa-
tients established a positive correlation between CRT exposure on the
plasma membrane of malignant blasts and the frequency of circulating
T cells speciﬁc for leukemia-associated antigens. This means that sur-
face exposure of CRT favors the initiation of anticancer immunity and
increases overall survival of patients with AML [39]. Although all these
studies point to increased expression of CRT as a favorable prognostic
marker, it is necessary to mention the other face of CRT. It has been
shown in 79 patients with gastric cancer that increased expression of
CRT in tumor tissue was associated with unfavorable prognosis and
increased risk of early cancer-related death. In combination with ex-
perimental work on cell cultures, the authors showed that CRT over-
expression increases cell proliferation and migration and upregulates
the expression and secretion of proangiogenic factors (e.g. VEGF, PlGF)
Box 2
Historical background: from Coley's toxins to the immunogenic cell death concept.
In the early 1700s, it was observed in clinical practice that some cancer patients who developed a bacterial infection had a remission from
cancer [74]. About 100 years later, in 1881, the American surgeon William B. Coley (the father of immunotherapy) tested this observation
by using erysipelas infection to treat patients with non-operable sarcoma [75]. Of interest, Coley was not the ﬁrst to undertake such a trial.
In 1868, W. Busch [76] made a similar attempt but on a smaller scale, even before the streptococcal etiology of erysipelas was known, and
similar work was repeated by F. Fehleisen in 1882, who discovered that streptococcus is the etiologic agent of erysipelas [74]. However, at
that time it was extremely problematic to control the process of infection. Some patients required re-infection while in others the infection
did not develop at all. After unsuccessful attempts, in 1892 Coley began to use a vaccine composed of heat-killed Gram-positive Strepto-
coccus pyogenes and Gram-negative Serratia marcescens (formerly known as Bacillus prodigiosus). By 1909, this combination (now known as
Coley's toxins) yielded some positive results in clinical practice [77] However, at that time there was no understanding of the mechanisms
of the positive eﬀects of infection on the reduction of tumor growth. Moreover, after Coley's death in 1936 and because of the emergence of
chemotherapy and radiotherapy, interest in such vaccines decreased sharply. Nevertheless, Coley's work is one of the ﬁrst reports of the
positive eﬀect of induction of inﬂammation in the tumor bed on tumor treatment. In the 1960s, when it became evident that long-term
control of cancer was not possible with the available treatments, interest in the clinical use of vaccines reemerged [78–80]. In the late
1980s, it was shown that immune cells can recognize pathogen-infected cells through recognition of pathogen-associated molecular pat-
terns (PAMPs), which are of viral or bacterial origin or are certain nucleic acid sequences of their genomes [81,82]. The current ICD
concept [3] is based on the “danger theory,” which was proposed in 1994 by Polly Matzinger [4,5].
Table 1
Prognostic and diagnostic aspects of DAMPs (CRT and HMGB1) in several types of cancer.
Type of cancer DAMPs level and prognosis Type of biomaterials Refs
Neuroblastoma Increased CRT: positive prognosis. Tissue sections of tumor (immunohistochemical study) [36]
Gastric cancer Increased CRT: high risk for early cancer-related death. Tumor tissue [40]
Bladder urothelial carcinoma Increased urinary CRT: diagnostic criterion of bladder tumor. Urine specimens [37]
Lung carcinoma CRT: correlates with malignancy and tumor grade. Serum samples [85]
Non-small cell lung cancer (NSCLC) Increased CRT: positive prognosis. Tumor tissue [38]
Аcute myeloid leukemia (AML) Increased CRT: positive prognosis. Peripheral blood[serum, peripheral blood mononuclear cells
(PBMCs)]
[39]
Esophageal squamous cell carcinoma
(ESCC)
HMGB1: expression increases overall survival.
CRT-strong and CRT-weak patients: no survival diﬀerence.
Peripheral blood lymphocytes (PBL).
Formalin-embedded tumor samples.
[44]
Localized breast cancer Increased nuclear HMGB1 in combination with LC3B: positive
life expectancy.
Breast cancer surgical specimens. [86]
Early breast cancer Immediate increasing HMGB1: improved outcome. Peripheral blood (plasma samples). [42]
Melanoma HMGB1: no signiﬁcant correlation between its expression and
patient survival.
Metastatic melanoma samples. [46]
Breast cancer HMGB1 and CRT expression: no eﬀect on pathological
response and overall survival.
Pre-treatment biopsy specimens and surgically resected
specimens.
[45]
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in gastric cancer cells, and also regulates the cancer progression-related
gene CTGF [40]. Therefore, additional studies are needed to resolve this
controversy and to determine whether these diﬀerences are cancer-type
dependent.
3.2. HMGB1
It has been reported that increased HMGB1 in the peripheral blood
during the ﬁrst few days of combined chemotherapy with epirubicin
and docetaxel can indicate early response to chemotherapy (Table 1).
Indeed, a signiﬁcant increase in HMGB1 was detected only in patients
who eventually showed pathological tumor regression, and no change
in HMGB1 was detected in the non-responder group [41]. Furthermore,
studies on 36 patients with early breast cancer showed that an early
increase in HMGB1 levels in the peripheral blood in response to che-
motherapy correlates with long-term survival [42]. Therefore, the level
of HMGB1 could be used as a valuable complementary biomarker for
early estimation of prognosis. Immunohistochemical analysis of tumor
specimens obtained from 232 patients with breast carcinoma revealed
that increased HMGB1 staining was associated with a smaller tumor
size. The loss of nuclear staining for HMGB1 was observed more fre-
quently in larger tumors [43]. A positive correlation between the level
of HMGB1 and survival of patients with esophageal squamous cell
carcinoma was also shown [44]. Yet, it is important to mention another
face of HMGB1. It has been shown that conventional chemotherapy
alone signiﬁcantly induced the upregulation of HMGB1 in breast cancer
and esophageal squamous cell carcinoma, indicating that some degree
of ICD can be signiﬁcantly induced after chemotherapy. However, there
was no signiﬁcant correlation between the level of HMGB1 and pa-
thological response after neoadjuvant chemotherapy, or between the
level of HMGB1 and survival [45]. It is important to mention that in
another study no signiﬁcant prognostic value was seen in any of the
tested biomarkers of immunogenic cell stress and death in melanoma:
microtubule-associated proteins 1A/1B light chain 3B (MAP-LC3B, best
known as LC3B), presence of nuclear HMGB1, phosphorylation of
eIF2α, and increase in cancer cell ploidy [46].
Taking all these clinical studies into consideration (Table 1), it is
clear that determination of the levels of DAMPs (CRT and HMGB1) in
biological materials can be used to assess the response to therapy and to
predict the course of the disease. However, these markers are not uni-
versal and can only be used for certain types of cancer or certain cohorts
of patients. The main question for future research is to understand why
the same DAMPs in one type of cancer are associated with a better
prognosis, while in other types they are associated with a worse prog-
nosis. To answer that question, it will be essential to characterize the
antigenic repertoire of tumors and to perform spectral analysis of
DAMPs and their modiﬁcation states in diﬀerent types of cancer.
4. Biomaterials and immunogenicity of cancer cell death
Delivery of diﬀerent chemotherapeutics via nanomaterials, in-
cluding liposomes, synthetic polymers, micelles, and inorganic nanos-
tructures, has been intensively investigated. In this section, we will
focus mainly on the chemotherapeutics belonging to the class of ICD
inducers and discuss how nanomaterials can be used to modulate the
anti-tumor immune responses induced by immunogenic cell death
(Table 2, Fig. 2).
4.1. Nano and micro-particles: an emerging strategy to increase the
immunogenicity of dying cancer cells
It has been shown that the delivery of ICD inducers packed into
nanoparticles signiﬁcantly increases their ICD potential (Table 2). Zhao
et al. [47] have shown that packaging into polymeric nanoparticles
[monomethoxy-poly(ethylene glycol)-poly(d,L-lactide-co-glycolide)]
increases the in vitro and in vivo eﬃcacy of oxaliplatin, a well-known
ICD inducer [48]. These results have shown that treatment of tumor
cells with nanoparticles containing oxaliplatin induced more release of
DAMPs and stronger immune responses of DCs and T lymphocytes in
vitro than oxaliplatin without nanoparticles. Moreover, the authors
showed that oxaliplatin incorporated in nanoparticles exhibited
stronger therapeutic eﬀects than free oxaliplatin in the murine tumor
prophylactic vaccination model [47]. It is noteworthy that loading a
non-immunogenic drug (5-ﬂuorouracil or gemcitabine) in the same
nanoparticles did not grant an immunogenic potential to the non-im-
munogenic chemotherapeutics, indicating that the immunogenic po-
tential is inducer-dependent [47]. It is important to mention that there
are also dual delivery carriers for chemotherapeutics for ICD induction
that can be co-delivered in the soft and hard nanocarrier platforms
together with lipid-conjugated immune-stimulatory compounds
(Table 2). This approach indeed might lead to more eﬀective anti-tumor
immune responses. In this regard, the immunogenic chemotherapeutic
oxaliplatin was co-delivered with an indoleamine 2,3 dioxygenase in-
hibitor (indoximod) conjugated to a phospholipid [49]. This strategy
ﬁrst allows the self-assembly of the prodrug indoximod into nanove-
sicles or its incorporation into a lipid bilayer that encapsulates meso-
porous silica nanoparticles. The core in these porous silica nano-
particles allows concurrent delivery of oxaliplatin. The authors showed
that nanovesicles plus free oxaliplatin or oxaliplatin together with in-
doximod nanoparticles induce eﬀective innate and adaptive immunity
against pancreatic ductal adenocarcinoma when used as a vaccine by
direct injection in the tumor or by intravenous biodistribution to an
orthotopic pancreatic ductal adenocarcinoma site [49]. The anti-tumor
eﬀects were associated mainly with recruitment of cytotoxic T lym-
phocytes and downregulation of Foxp3+ T cells. It is also possible to
induce robust antitumor immunity with nanoparticles loaded with ICD-
chemotherapy that can also sensitize tumors to immune checkpoint
blockade. To this end, synthetic high-density lipoprotein (sHDL)-like
nanodiscs have recently been developed [50]. The nanodiscs are com-
posed of an apolipoprotein A1 mimetic peptide and phospholipids to
provide stimuli-responsive delivery of doxorubicin [50]. In this study,
the authors demonstrated that doxorubicin formulation in sHDL na-
nodiscs markedly potentiated the antitumor T cell responses and the
therapeutic eﬃcacy of αPD-1 immunotherapy, leading to elimination of
established CT26 and MC38 colon carcinoma in 80 to 88% of the mice,
inhibition of CT26 liver metastasis, and induction of long-term im-
munity against re-challenge with tumor cells. The authors showed that
doxorubicin-carrying nanodiscs led to robust antitumor CD8+ T cell
responses while broadening their epitope recognition to tumor-asso-
ciated antigens, neoantigens, and intact whole tumor cells [50].
Of interest, cancer cells dying by an ICD modality can be converted
into a versatile platform for cancer vaccination, at least in murine
tumor models. Fan et al. [51] used dying colon carcinoma CT26 and
melanoma B16 cells undergoing ICD as the source of both tumor anti-
gens and “danger” signals and ampliﬁed their potency by surface-
modiﬁcation of dying tumor cells with nano-multilayered particles
containing CpG (Table 2). CpG is an adjuvant and a potent TLR-9
agonist known to promote antigen cross-presentation and cross-priming
of CD8+ T-cell responses. The authors coupled nanoparticles loaded
with CpG onto the surfaces of dying tumor cells via sulfhydryl-mal-
eimide chemistry. This strategy was very eﬃcient because im-
munogenically dying tumor colon carcinoma CT26 cells (i.e. killed by
mitoxantrone in vitro) and decorated with CpG-nanoparticles promoted
DC maturation as well as antigen cross-presentation, leading to robust
antigen-speciﬁc T-cell responses with antitumor activity in vivo [51].
Although this study shows for the ﬁrst time that surface modiﬁcation of
cancer cells undergoing ICD with nanocarriers containing a potent ad-
juvant is a promising novel experimental “personalized” therapy, ad-
ditional research is needed to adapt this strategy to co-deliver, for ex-
ample, ICD inducers together with adjuvants to tumors as vaccines
without ex vivo manipulations.
The eﬃciency of nanoparticles as nanocarriers of
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chemotherapeutics for modulation of anti-tumor-immune responses is
greatly dependent on their size, which in fact is a double-edged sword.
On the one hand, smaller nanoparticles increase penetration into the
tumors, mainly via the leaky tumor vasculature [52]. On the other
hand, larger nanoparticles have signiﬁcantly larger retention capacity
[53]. Therefore, it is clear that nanoparticles of ﬁxed size are not op-
timal. One way to cope with this dilemma is to design nanoparticles
with changeable size. Mei et al. [54] developed DSPE-PEG micelles with
sizes that can changed by using chemical reactions. First, the micelles
modiﬁed with azide or alkyne group are 25 nm in size, which optimizes
their penetration into the tumor bed. But once they reach the tumor
bed, micelles increase in size to ~120 nm due to a chemical reaction,
and this increases their retention and accumulation. The authors used
this strategy to co-deliver doxorubicin and monophosphoryl lipid A, an
adjuvant that is an agonist of TLR-4, to induce ICD and thereby further
promote the maturity and antigen presentation of DCs in order to in-
duce strong eﬀector T cells in vivo that can suppress tumor growth and
prevent tumor metastasis. This study demonstrates a technological
platform for changing the size of nano-particles to improve their pe-
netration and accumulation in the tumors.
4.2. Nano-carries to trigger ICD in order to reduce serious complications of
cancer therapy
Another positive aspect of using nano-carriers to trigger ICD is re-
duction of the serious complications of cancer therapy [55], which
frequently compromise treatment and dramatically reduce the quality
of life of patients. Furthermore, these strategies can increase the im-
munogenicity of dying cancer cells, enabling the development of ef-
fective anti-tumor immune responses (Table 2, Fig. 2). Nanoparticle
delivery can reduce the side eﬀects by redistributing drug accumulation
away from critical organs such as the heart and intestine. They also
permit the administration of larger doses than it is possible with a free
drug. In this context, it has been shown that when the cytotoxic drug
pirarubicin, a commonly used anthracycline and ICD inducer, was en-
trapped into nanostructured lipid carriers, it led to reduced myelosup-
pression but at the same time it enhanced anti-tumor eﬀects in mice
bearing 4 T1 breast tumors [56]. Another immunogenic anthracycline,
doxorubicin [57,58], was loaded into a nanoparticle delivery system
based on conjugation of multiple copies of doxorubicin to one end of
the chimeric recombinant polypetide via an acid-labile bond [59]. In
this recent work, the authors showed that CD8+ cells and IFN-γ are
necessary for the full eﬃcacy of the chimeric polypetide-doxorubicin
formulation, whereas their depletion had no eﬀect in mice bearing 4 T1
mammary carcinoma and treated with freely dissolved doxorubicin
Fig. 2. Nano-particles and micro-particles: an emerging strategy to modulate the immunogenicity of immunogenic cell death.
Biomaterials are widely used to modulate the eﬀectiveness of chemotherapeutics in experimental anti-cancer therapy. (1) Delivery of chemotherapeutics via bio-
materials (e.g. polymer nanoparticles, micelles, dendrimers and liposomes) increases their immunogenicity (Table 2) and eﬀectiveness in anti-cancer therapy, leading
to decreased metastasis and longer survival. (2) Immunogenicity can often be ampliﬁed by co-delivery of TLR agonists or IDO inhibitors by using dual delivery
carriers to obtain simultaneous delivery of chemotherapeutics and adjuvants. The use of adjuvants with the main chemotherapeutics can enhance the engagement of
immune responses towards ICD. (3) Another beneﬁt of the delivery of chemotherapeutics in nanocarriers is the ability to reduce the drug dose. Encapsulation of the
drugs in nanoparticles signiﬁcantly reduces their toxicity to the host cells. Nanoparticle delivery systems also avoid drug accumulation in critical organs (e.g. heart,
intestine) and permit the administration of larger doses, which is not possible with a free drug. All these strategies are being tested in experimental mouse models,
and other studies are needed to translate the ﬁndings to the clinical settings.
Abbreviations: ICD, immunogenic cell death; IDO inhibitor, indoleamine 2,3 dioxygenase inhibitor TLR, Toll like receptors.
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[60]. These studies underline an interesting and important aspect of the
immunomodulatory eﬀects of doxorubicin in mice, that it can be en-
hanced by a nanoparticle delivery system even in a poorly im-
munogenic model system such as 4 T1 mammary carcinoma. This is
very relevant clinically because weakly immunogenic tumors are one of
the main problems of current anti-cancer therapy [61]. Indeed, the
study by Mastria et al. [62] is distinct from the studies in which the
immunogenicity of doxorubicin loaded into PEGylated liposomes
(Doxil) was validated in the CT26 and MCA205 cancer models, which
are immunogenic cancer cell lines. These authors demonstrated that the
Doxil formulation was more eﬀective in immunocompetent mice and
synergized with checkpoint blockade (i.e. anti-PD-1 and CTLA-4 mAbs)
in CT26 and MCA205 tumor models [62]. Of note, that these check-
point inhibitors have been approved by the Food and Drug Adminis-
tration, USA, as a therapy for several types of cancer, including mela-
noma and non-small cell lung cancer [63]. For this discovery, James P.
Allison and Tasuku Honjo have been awarded the Nobel Prize in Phy-
siology or Medicine in 2018. Interestingly, several studies have in-
dicated that the anti-tumor immunity induced by ICD may be re-
inforced by anti-PD-1 and anti-CTLA-4 drugs. For example, it has been
shown that Dinaciclib induces immunogenic cell death and enhances
anti-PD1-mediated tumor suppression [64].
Another approach to reduce the side eﬀects of chemotherapy is to
reduce the dose. However, due to the strong immunosuppressive en-
vironment of certain tumors (i.e. melanoma driven by B-Raf proto-on-
cogene (BRAF) mutation), low doses of doxorubicin often lead only to a
partial response [65]. Of note, the immunosuppressive environment of
BRAF mutant melanoma cells is highly dependent on Wnt family
member 5A (Wnt5a), which contributes to the induction of DC toler-
ance and tumor ﬁbrosis [66], thereby hindering eﬀective antigen pre-
sentation. In order to reduce the immunosuppressive eﬀects, which are
mediated by Wnt5a signaling, the authors validated the extracellular
domain of Fizzled 7 receptor, which as a trimeric trap protein binds
Wnt5a with a Kd of ~ 278 nM [65]. Moreover, plasmid DNA packed
into cationic lipid-protamine-DNA nanoparticles was used to deliver the
Wnt5a trap. This strategy was very eﬀective in signiﬁcantly inhibiting
tumor growth and increasing host survival, suggesting that local Wnt5a
trapping signiﬁcantly remodels the immunosuppressive tumor micro-
environment to facilitate immunogenic cell-death-mediated im-
munotherapy at low doses of ICD inducer. Future studies will show
whether nanomaterials are truly a better strategy for increasing the
immunogenicity of dying cancer cells while reducing the severe side
eﬀects. Future studies will also provide the insights needed for the
development of novel treatment strategies for cancer.
5. Concluding remarks and future perspectives
Only about one decade ago, apoptosis was considered as im-
munologically neutral or even anti-inﬂammatory and immuno-sup-
pressive [10–12]. However, insights from the last decade increasingly
support the view that certain anti-cancer treatment modalities can in-
duce ICD (i.e. immunogenic apoptosis), which contributes to anti-tumor
immune responses. Moreover, it is clear that ICD is an umbrella term
that covers a broad range of diﬀerent types of cell death, including
apoptosis, necroptosis, and other immunogenic cell modalities (Box 2).
On one hand, recent studies suggest that nanomaterials can be used
to amplify the immunogenicity of cancer cell death (Table 2) and to
reduce the severe side eﬀects of anti-cancer therapy. These ﬁndings
should be validated in clinically relevant tumor models and ex vivo.
However, intriguing questions remain, such as how feasible these for-
mulations are in the clinical setting, when large-scale manufacturing
and proven human safety are required. For example, nanoparticles ty-
pically require PEGylation to obtain suﬃcient circulation half-life and
compound accumulation in the tumor bed, but this could lead to
chronic-foot syndrome [67] and generation of anti-PEG (polyethylene
glycol) antibodies [68], which can delay their clinical application.
Further research is also needed to develop nanomaterials with catalytic
properties that can be used for sequential induction of ICD, ER stress
and ROS and at the same time induce the release of the DAMPs and
cytokines/chemokines required for the immunogenicity of dying cancer
cells.
On the other hand, current interest is focused on the development of
nanoparticles as targeted delivery systems for induction of ICD, i.e.
immunogenic apoptosis. But cancer cells often develop resistance to
apoptosis [30], so novel strategies are needed to trigger alternative
forms of death in cancer cells. Recently, it has been shown that drugs
can be successfully nanotargeted to induce ferroptosis (Box 1) in cancer
cells [69]. It is noteworthy that nanomaterials can even be provided
with direct cell death inducing capabilities, which might turn out to be
a promising therapeutic option. It has been shown that ultrasmall silica
nanoparticles (< 10 nm in diameter) coated with poly(ethylene glycol)
(PEG) and functionalized with melanoma-targeting peptides can induce
ferroptosis (Box 1) [70]. This study opens possibilities to develop
strategies that allow the design of nanoparticles with dual properties:
targeting delivery of ICD inducers to the tumor bed and possession of
intrinsic capacities to trigger diﬀerent cancer cell death modes (apop-
tosis, necroptosis, or ferroptosis). This may lead to synchronous and
selective killing of cancer cells, which are most susceptible to speciﬁc
types of cell death. Future studies will provide the necessary insights
needed for the development of novel treatment strategies to increase
the immunogenicity of cancer cell death by using nanomaterials and to
validate these strategies in clinical settings. That is an exciting area for
upcoming research.
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